New Study Shows Rapid EGFR testing with Idylla!

Products are for professional/laboratory use only. Large UK Study Shows Rapid EGFR Testing with Idylla™ Alongside NGS Has Potential to Enhance Lung Cancer Patient Health Outcomes

Study Reviewing 2,500 Performed Idylla Tests Shows Generation of Valid Results in 98.1% of Cases and Outperformance over Reference Methods

Products are for professional/laboratory use only. Press Release:  Mechelen, Belgium, 27 June 2018

Biocartis Obtains Exclusive Worldwide License Rights for EGFR Ectodomain Mutations Determining Response to Targeted Colorectal Cancer Therapy

Products are for professional/laboratory use only. PRESS RELEASE: 28 August 2018 Mechelen, Belgium, 28 August 2018 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that it has obtained exclusive worldwide license rights for highly innovative EGFR ectodomain mutations that have shown to determine response to […]

Study Demonstrates Ability of Idylla EGFR Mutation Test to Produce a Result in 80% of Failed Next Generation Sequencing Lung Cancer Tests

Products are for professional/laboratory use only. A new publication in the Journal of Clinical Pathology demonstrated that the Idylla EGFR Mutation Test (CE-IVD) was able to rescue 80% of the EGFR samples whose assessment was unsuccessful with Next Generation Sequencing (NGS).

Idylla EGFR Mutation Test (CE-IVD)

Products are for professional/laboratory use only. Biocartis is pleased to add a new Idylla EGFR (Epidermal Growth Factor Receptor) Mutation Test to their core oncology menu, that now covers most known and used oncology biomarkers.